Marie Sklodowska-Curie Actions (MSCA)

About this programme

Marie Sklodowska-Curie Fellowships are European research grants available to researchers regardless of their nationality or field of research. In addition to generous research funding scientists have the possibility to gain experience abroad and in the private sector, and to complete their training with competences or disciplines useful for their careers.

MSCA – Key Features:

  • Open to all domains of research and innovation from basic research up to market take-up and innovation services
  • Entirely bottom-up
  • Participation of non-academic sector strongly encouraged, especially industry and SMEs
  • Mobility as the key requirement - funding on condition participants move from one country to another
  • Promotion of attractive working and employment conditions
  • Particular attention to gender balance
  • Public engagement of supported researchers

There are five types of Marie Sklodowska-Curie Actions:

  • Individual Fellowships (IF)
  • Innovative Training Networks (ITN)
  • Research and Innovation Staff Exchange (RISE)
  • Co-funding of regional, national and international programmes (COFUND)
  • European Researchers’ Night (NIGHT)
Click to read more 
Hide text 

Your NCP contact for this programme

Image of Margot Beereboom

Margot Beereboom

margot.beereboom@fwo.be

+32 2 550 15 76

Latest news

Upcoming events

No events that are specifically related to Marie Sklodowska-Curie Actions (MSCA) were found. Check the full calendar.

Infosheets

Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.

    No infosheets available for this domain

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.